Deborah Borgman
Primary Care · Houston, TXNPI 1073898896
Payments from drug & device makers
Across 79 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$389
- AstraZeneca$255
- AbbVie$145
- Lilly USA, LLC$140
- Paratek Pharmaceuticals, Inc.$86
- Abbott$79
- plus $504 from 18 others
What the payments were for
- Food & beverage$1,600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $389 |
| AstraZeneca | 9 | $255 |
| AbbVie | 7 | $145 |
| Lilly USA, LLC | 7 | $140 |
| Paratek Pharmaceuticals, Inc. | 4 | $86 |
| Abbott | 4 | $79 |
| Kowa Pharmaceuticals America, Inc. | 4 | $70 |
| Exact Sciences | 2 | $47 |
| Novartis | 2 | $44 |
| Antares Pharma, Inc. | 2 | $41 |
| Amgen | 2 | $40 |
| Bayer | 2 | $39 |
| Neos Therapeutics, LP | 2 | $37 |
| GSK | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$126
How this compares
$1,600 in reported general payments places this provider in the 80th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $64,653 |
| MounjaroTirzepatide | 49 | $53,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $27,016 |
| FarxigaDapagliflozin Propanediol | 12 | $11,721 |
| EliquisApixaban | 11 | $8,570 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $3,993 |
| Methazolamide | 13 | $2,917 |
| Gabapentin | 88 | $1,699 |
| Levothyroxine Sodium | 128 | $1,543 |
| Metoprolol Succinate | 66 | $1,460 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,373 |
| Rosuvastatin Calcium | 82 | $1,114 |
| Atorvastatin Calcium | 111 | $862 |
| Tamsulosin Hcl | 58 | $846 |
| Ventolin HfaAlbuterol Sulfate | 15 | $795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $389 | $64,65347 claims |
| Lilly USA, LLCMounjaro | $140 | $53,18349 claims |
| GSKTrelegy Ellipta | $24 | $27,01638 claims |
| AstraZenecaFarxiga | $255 | $11,72112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 563 primary care providers in Texas.
Other primary care in Houston
- Mary GibbensHouston$42K
- Joanna LarsonHouston$7K
- Mei ChenHouston$4K
- Catherine PenceHouston$3K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Roxana RoposGrapevine$13K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.